:: Volume 10, Issue 2 (1-2022) ::
gebsj 2022, 10(2): 183-189 Back to browse issues page
Anti-proliferative effect and apoptotic induction of sesquiterpene lactone parthenolide in a human breast cancer cell line MDA-MB- 231
Nesa Jafari * , Sonbol Nazeri , Sareh Arjmand , Reza Behroozi , Kobra Nalbandi , Sattar Tahmasebi Enferadi
Department of Plant Biotechnology, Faculty of Agriculture, Bu-Ali Sina University, Hamadan, Iran. , jafari.nesa@gmail.com
Abstract:   (3201 Views)
Parthenolide is a secondary metabolite, which naturally occurs in the feverfew plant (Tanacetum parthenium) and is responsible for its healing power. The potential of parthenolide in inhibition of cancer cell growth, alone or in combination with other anti-cancer therapeutics, has been studied in several laboratories. In this study, the effect of extracted parthenolide on the expression of seven pro-apoptotic genes (BID, P21, PUMA, BAX2, P53, CASP8 and BIM), all of them were influenced by NF-κB signaling pathway, in MDA-MB- 231, a breast cancer cell line was investigated. The results indicated that in response to the parthenolide treatment, all of the selected genes were induced and up-regulated significantly with different degrees. We proved that parthenolide alters the expression of a variety of genes involved in apoptosis pathway in MDA-MB- 231 cell line. In conclusion, we provided evidence that parthenolide alters the expression of a variety of genes involved in apoptosis pathway in MDA-MB- 231 breast cancer cells. The selected genes are directly or indirectly were regulated by NF-κB and it is confirmed that NF-κB is an important target of parthenolide.
Keywords: Apoptosis, MDA-MB- 231 cell line, Parthenolide, Real time PCR
Full-Text [PDF 647 kb]   (1059 Downloads)    
Type of Study: Research | Subject: Divers
Received: 2021/06/21 | Accepted: 2021/11/7 | Published: 2021/12/14


XML   Persian Abstract   Print



Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 10, Issue 2 (1-2022) Back to browse issues page